Prophylactic Urethral Stenting With Memokath After Prostate Implantation for Prostate Adenocarcinoma

Completed · Phase 1/Phase 2

Conditions studied: Prostate Cancer, Post-Brachytherapy Bladder Outlet Obstruction

In brief

The purpose of this study is to determine the feasibility, safety, and efficacy of the Memokath® 028SW stent to prevent urinary obstructive symptoms (difficulty urinating) when used after prostate seed implantation for the treatment of localized prostate cancer.

Key facts

Study ID

NCT00252941

Run by

The Cleveland Clinic

People needed

20

Starts

2005-11-01

Expected to finish

2006-11-01

Last updated by the study team

2010-12-21

Who can join

Age: 50 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• eligible for prostate seed implant
• 50 years of age or older
• able to give informed consent

You may not qualify if…

• presence of any other urologic implant, including stents,penile prosthesis or artificial sphincter
• history of transurethral resection of prostate (TURP)procedure
• presence of urethral diverticuli
• presence of urethral strictures
• presence of bladder calculi or tumors
• prostatic urethra is less than 2.5 cm or greater than 6.5 cm
• inability to participate in study activities due to physical or mental limitations
• inability or unwillingness to return for all the required follow-up visits

Where it is running

• Cleveland Clinic Foundation — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.